JAMA Network
About The Study: Despite rapid expansion of ultraexpensive drugs in Medicare Part D, this cohort study found that availability in comparable economies remains limited, and internationally unavailable products often have higher per-beneficiary spending, underscoring their fiscal significance.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
